Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.

Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold JS.

Clin Cancer Res. 2016 Jan 15;22(2):405-14. doi: 10.1158/1078-0432.CCR-15-0829. Epub 2015 Sep 14.

2.

Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer.

Dosch JS, Ziemke EK, Shettigar A, Rehemtulla A, Sebolt-Leopold JS.

Cancer Res. 2015 Nov 1;75(21):4582-92. doi: 10.1158/0008-5472.CAN-14-2793. Epub 2015 Sep 10.

Supplemental Content

Loading ...
Support Center